GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » US Neurosurgical Holding Inc (OTCPK:USNU) » Definitions » Research & Development

US Neurosurgical Holding (US Neurosurgical Holding) Research & Development : $0.00 Mil (TTM As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is US Neurosurgical Holding Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. US Neurosurgical Holding's Research & Development for the three months ended in Mar. 2024 was $0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil.


US Neurosurgical Holding Research & Development Historical Data

The historical data trend for US Neurosurgical Holding's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

US Neurosurgical Holding Research & Development Chart

US Neurosurgical Holding Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

US Neurosurgical Holding Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

US Neurosurgical Holding Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


US Neurosurgical Holding  (OTCPK:USNU) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


US Neurosurgical Holding Research & Development Related Terms

Thank you for viewing the detailed overview of US Neurosurgical Holding's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.


US Neurosurgical Holding (US Neurosurgical Holding) Business Description

Traded in Other Exchanges
N/A
Address
2400 Research Boulevard, Suite 325, Rockville, MD, USA, 20850
US Neurosurgical Holding Inc operates as a holding company in United State. It is a medical services company that partners with hospitals and physicians to operate facilities utilizing artistic and inventive technologies in medical treatment and diagnosis. It is engaged in providing medical treatment and diagnosis services that include stereotactic radiosurgery centers, utilizing gamma knife technology, and holds interests in radiological treatment facilities. The company is focusing on establishing cancer centers using intensity-modulated radiation therapy. Its gamma knife is a stereotactic radiosurgical device used to treat brain tumors and other malformations of the brain without invasive surgery.
Executives
Lawrence William St director 23 ASHLAND STREET, NEWBURYPORT MA 01950-1905
William F. Leimkuhler director 43 SALEM STRAITS RD, DARIEN CT 06820
Merriman Charles H Iii director
Alan Gold director, 10 percent owner, officer: President & Chairman 2400 RESEARCH BLVD, SUITE 325, ROCKVILLE MD 20850
Stanley S Shuman 10 percent owner C/O RIPPLEWOOD HOLDINGS LLC, ONE ROCKERFELLER PLAZA, NEW YORK NY 10020
Allen & Co Inc 10 percent owner 711 FIFTH AVENUE, NEW YORK NY 10022

US Neurosurgical Holding (US Neurosurgical Holding) Headlines

No Headlines